ziyad al aly glp 1 Al-Aly, MD, FASN | Division of General Medicine & Geriatrics Stopping or interrupting GLP-1 usage
Description
Applying Pressure at the State Level With the FDA declining to ban compounded GLP-1s outright, trade groups shifted focus to state regulators
These medications are approved by the Food and Drug Administration (FDA) for the treatment of obesity or overweight with weight-related comorbidities
[DOI] [PubMed] [Google Scholar] 17.A randomized, controlled trial of liraglutide for adolescents with obesity
Understanding its effects establishes the baseline against which all subsequent escalations are measured
